Tough Times Ahead for Public Biotechs in Need of Cash
By Catherine Hollingsworth
Monday, October 20, 2008
As investors remain skittish about the economy, financing options for cash-strapped, publicly traded biotech companies have dwindled. The outlook for the therapeutic biotech industry is somewhat brighter for venture-backed private biotech companies and public companies in a comfortable cash position, but many other biopharmaceutical companies are in a financial pinch. And until the economic turmoil stabilizes, there are few options for public traded biotechs looking to raise cash, industry sources told BioWorld Financial Watch.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.